|
United Therapeutics Corp Common
(UTHR)
|
14.9 |
$1.0B |
|
2.9M |
358.35 |
|
Ascendis Pharma Sponsored ADR
(ASND)
|
10.9 |
$745M |
|
5.0M |
149.31 |
|
Argenx Se Sponsored ADR
(ARGX)
|
9.8 |
$671M |
|
1.2M |
542.08 |
|
Krystal Biotech Common
(KRYS)
|
7.0 |
$477M |
|
2.6M |
182.03 |
|
Madrigal Pharmaceuticals Common
(MDGL)
|
6.3 |
$431M |
|
2.0M |
212.22 |
|
Apellis Pharmaceuticals Common
(APLS)
|
4.7 |
$320M |
|
11M |
28.84 |
|
Sarepta Therapeutics Common
(SRPT)
|
4.7 |
$319M |
|
2.6M |
124.89 |
|
Avidity Biosciences Common
(RNA)
|
4.6 |
$316M |
|
6.9M |
45.93 |
|
Amicus Therapeutics Common
(FOLD)
|
3.6 |
$248M |
|
23M |
10.68 |
|
Intra-cellular Therapies Common
(ITCI)
|
3.3 |
$223M |
|
3.1M |
73.17 |
|
Xenon Pharmaceuticals Common
(XENE)
|
3.3 |
$223M |
|
5.7M |
39.37 |
|
Kymera Therapeutics Common
(KYMR)
|
3.1 |
$213M |
|
4.5M |
47.33 |
|
Vera Therapeutics Common
(VERA)
|
2.8 |
$191M |
|
4.3M |
44.20 |
|
Arrowhead Pharmaceuticals Common
(ARWR)
|
2.5 |
$172M |
|
8.9M |
19.37 |
|
Biomarin Pharmaceutical Common
(BMRN)
|
2.1 |
$143M |
|
2.0M |
70.29 |
|
Moonlake Immunotherapeutics Class A Ord
(MLTX)
|
2.0 |
$140M |
|
2.8M |
50.42 |
|
Vaxcyte Common
(PCVX)
|
2.0 |
$134M |
|
1.2M |
114.27 |
|
Soleno Therapeutics Common
(SLNO)
|
1.6 |
$110M |
|
2.2M |
50.49 |
|
Biocryst Pharmaceuticals Common
(BCRX)
|
1.3 |
$90M |
|
12M |
7.60 |
|
Syndax Pharmaceuticals Common
(SNDX)
|
1.1 |
$75M |
|
3.9M |
19.25 |
|
Ocular Therapeutix Common
(OCUL)
|
1.0 |
$70M |
|
8.1M |
8.70 |
|
Kura Oncology Common
(KURA)
|
1.0 |
$69M |
|
3.5M |
19.54 |
|
Merus N V Common
(MRUS)
|
1.0 |
$68M |
|
1.4M |
49.96 |
|
Tourmaline Bio Common
(TRML)
|
0.8 |
$57M |
|
2.2M |
25.71 |
|
Mannkind Corp Common
(MNKD)
|
0.8 |
$55M |
|
8.8M |
6.29 |
|
Ultragenyx Pharmaceutical Common
(RARE)
|
0.7 |
$46M |
|
830k |
55.55 |
|
Autolus Therapeutics Sponsored ADR
(AUTL)
|
0.7 |
$45M |
|
12M |
3.63 |
|
Iovance Biotherapeutics Common
(IOVA)
|
0.6 |
$40M |
|
4.2M |
9.39 |
|
Taysha Gene Therapies Common
(TSHA)
|
0.5 |
$38M |
|
19M |
2.01 |
|
Monte Rosa Therapeutics Common
(GLUE)
|
0.4 |
$31M |
|
5.8M |
5.30 |
|
Cg Oncology Common
(CGON)
|
0.4 |
$26M |
|
700k |
37.73 |
|
Dyne Therapeutics Common
(DYN)
|
0.3 |
$23M |
|
650k |
35.92 |
|
Spyre Therapeutics Common
(SYRE)
|
0.3 |
$18M |
|
599k |
29.41 |
|
Aadi Biosciences Common
(WHWK)
|
0.1 |
$5.9M |
|
2.8M |
2.06 |
|
Neurogene Common
(NGNE)
|
0.0 |
$924k |
|
22k |
41.96 |
|
Insmed Common Put Option
|
0.0 |
$125k |
|
50k |
2.50 |